CLDX 10-Q: SEC filing
Celldex Therapeutics
Filed with the SEC on · accession 0001104659-26-123322
CLDX filed a 10-Q (quarterly report) with the SEC on Nov 5, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved -5.5% by the first close after the filing.
Summary of the filing
Celldex Therapeutics filed its quarterly 10-Q report for the period ended September 30, 2026, disclosing routine financial results and business updates for its clinical-stage biopharmaceutical operations.
Key details
How CLDX stock reacted
Close before
$29.93
Nov 4, 2026
First close after
-5.55%
$28.27
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for CLDX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for CLDX?
Click hereFrequently asked questions
What did CLDX file with the SEC on Nov 5, 2026?
CLDX filed a 10-Q (SEC filing). Celldex Therapeutics filed its quarterly 10-Q report for the period ended September 30, 2026, disclosing routine financial results and business updates for its clinical-stage biopharmaceutical operations.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
How did CLDX stock react to this filing?
CLDX closed at $29.93 before the filing and $28.27 on Nov 5, 2026 (-5.55%).
Other CLDX SEC filings
Get alerts when CLDX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days